A phase 2 evaluation of oral LY317615 in patients with relapsed or refractory diffuse large B-Cell lymphoma

Trial Profile

A phase 2 evaluation of oral LY317615 in patients with relapsed or refractory diffuse large B-Cell lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2008

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2007 The expected completion date for this trial is now 1 Jan 2009.
    • 25 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top